Logo
JNJ logo
Johnson & Johnson
JNJ
246.28 (-0.04%) 0.09
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.

Quality Checklist 6/8

5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $593.51(B)
EV: $620.72(B)
Total Equity: $81.54(B)
Earnings date: Apr-14-2026
P/E: 22.13
Forward P/E: 21.36
P/FCF: 30.11
P/S: 6.29
P/B: 7.27
EPS: $11.1
EPS (fwd): $11.5
FCF/share: $8.2
Revenue/share: $39.1
Book value/share: $33.9
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.60
Current Ratio: 1.00
Gross margin: 68.1%
Operating margin: 26.2%
Net margin: 28.5%
Dividend/share: $5.1
Div. yield: 2.09%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

JNJ Valuation & Price Targets

Current Price
$246

Favorite Valuation Methods

PEvaluation
N/A
Analyst targets
N/A
DCF (2-stage)
N/A

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

21% overvalued
Low
$145
Mid
$194
High
$242
Current price
$246
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+111.411.511.724
FY+211.812.513.125
FY+312.313.614.813
FY+413.514.916.78
FY+514.016.418.87

Analyst Price Targets

4% overvalued
Low
$155
Mid
$237
High
$265
Current price
$246

Analyst Recommendations

Strong Buy5
Buy9
Hold10
Sell0
Strong Sell1

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$94.19(B)
Gross profit$64.13(B)
EBITDA$33.84(B)
Net income$26.80(B)
Gross margin68.1%
Operating margin26.2%
Net margin28.5%
Shares outstanding2.41(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$199.21(B)
Current assets$55.62(B)
Total liabilities$117.67(B)
Current liabilities$54.13(B)
Cash & Short-term inv.$20.10(B)
Long-term debt$39.44(B)
Total intangibles$99.17(B)
PP&E$24.47(B)

Cash flow (TTM)

CFOCFICFF
FCF$19.70(B)
CapEx$-4.83(B)
Dividends paid$-12.38(B)
Stock issued$3.42(B)
Stock repurchased$-5.95(B)
Stock-based comp.$1.35(B)
Debt issued$23.72(B)
Debt repaid$-14.09(B)

Per share data (TTM)

Price: $246
Revenue: $39.1 (6.3x | 15.9%) Gross profit: $26.6 (9.3x | 10.8%) Earnings: $11.1 (22.1x | 4.5%)
FCF: $8.18 (30.1x | 3.3%) Stock-based Comp.: $0.56 (438.3x | 0.2%) CapEx.: $2.01 (122.8x | 0.8%) Dividend: $5.14 (47.9x | 2.1%)
Total Assets: $82.7 (3.0x | 33.6%) Total Liabilities: $48.8 (5.0x | 19.8%) Book Value: $33.9 (7.3x | 13.7%) Cash & ST inv.: $8.34 (29.5x | 3.4%) Debt: $16.4 (15.0x | 6.6%)
Earnings FY+1: $11.5 (21.4x | 4.7%) Earnings FY+2: $12.5 (19.6x | 5.1%) Earnings FY+3: $13.6 (18.1x | 5.5%) Earnings FY+4: $14.9 (16.5x | 6.1%) Earnings FY+5: $16.4 (15.0x | 6.7%)
FCF FY+1: $10.5 (23.4x | 4.3%) FCF FY+2: $10.9 (22.6x | 4.4%) FCF FY+3: $12.3 (20.0x | 5.0%) FCF FY+4: $14.1 (17.5x | 5.7%) FCF FY+5: $15.1 (16.3x | 6.1%)

Summary

Growth Estimates

Revenue

CAGR: 5.8%
FY+1FY+2FY+3FY+4FY+5
FY+1$100.59(B)
FY+2(+5.3%)$105.94(B)
FY+3(+6.3%)$112.64(B)
FY+4(+5.8%)$119.20(B)
FY+5(+5.9%)$126.23(B)

Net Income

CAGR: 8.4%
FY+1FY+2FY+3FY+4FY+5
FY+1$28.09(B)
FY+2(+8.3%)$30.44(B)
FY+3(+8.0%)$32.86(B)
FY+4(+8.2%)$35.57(B)
FY+5(+9.1%)$38.81(B)

EPS

CAGR: 9.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$11.53
FY+2(+8.8%)$12.54
FY+3(+8.8%)$13.64
FY+4(+9.4%)$14.92
FY+5(+10.1%)$16.43

FCF per share

CAGR: 9.5%
FY+1FY+2FY+3FY+4FY+5
FY+1$10.51
FY+2(+3.5%)$10.88
FY+3(+13.2%)$12.32
FY+4(+14.0%)$14.05
FY+5(+7.6%)$15.12

Historical Financials

Showing limited histrical data.
TTM (Y)TTM (Q)FYFQ
Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.0(B)10.0(B)15.0(B)20.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.050.0(B)100.0(B)150.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.04.06.08.010.012.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.010.015.020.025.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%20%40%60%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%5%10%15%20%25%30%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0500.0(M)1.0(B)1.5(B)2.0(B)2.5(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0100.0(B)200.0(B)300.0(B)400.0(B)
Market Cap.

KPIs

Revenue By Geography(show more...)
9/202312/20233/20246/20249/202412/20243/20256/20259/202512/2025
Western Hemisphere Excluding US Asia Pacific and Africa United States Europe
Revenue By Segment(show more...)
9/202312/20233/20246/20249/202412/20243/20256/20259/202512/2025
Medtech Pharmaceutical Consumer Health

JNJ vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.05%
Institutions: 75.63%
Other: 24.31%

Institutional ownership

9.97% Vanguard Group Inc8.66% Blackrock Inc.5.55% State Street Corporati...2.43% JPMORGAN CHASE & CO2.40% Geode Capital Manageme...1.92% Morgan Stanley1.39% NORGES BANK1.31% State Farm Mutual Auto...1.24% Northern Trust Corpora...1.18% Bank of America Corpor...39.58% Others

Trading Summary

In the past year, insiders have bought $257688 worth of the company's stock, and sold $66.23(M).

Congress members have bought between $126028 - $665000 worth of the company's stock, and sold between $213030 - $895000.

Insider transactions

$0.002026-03$0.00
$0.002026-02$0.00
$22.12(M)2026-01$0.00
$0.002025-12$0.00
$0.002025-11$257688
$4.19(M)2025-10$0.00
$10.04(M)2025-09$0.00
$25.52(M)2025-08$0.00
$3.13(M)2025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$0.002025-04$0.00
$0.002025-03$0.00
DateSharesTotal ($)Price ($)NameTitle
Grant2026-02-0615,5711,586,218101.9SCHMID TIMOTHYOfficer
Grant2026-02-065,625573,019101.9MULHOLLAND KRISTENOfficer
Grant2026-02-0638,9453,967,327101.9WENGEL KATHRYN EChief Technology Officer
Grant2026-02-058,9211,155,359129.5FORMINARD ELIZABETHOfficer
Sell2026-01-26100,00022,122,893221.2DUATO JOAQUIN BOIXChief Executive Officer
Buy2025-11-261,250257,688206.2MORIKIS JOHN GDirector
Sell2025-10-1721,7214,185,793192.7REED JOHN COfficer
Grant2025-10-1721,7213,430,180157.9REED JOHN COfficer
Sell2025-09-0456,47110,040,883177.8TAUBERT JENNIFER LOfficer
Grant2025-09-0456,4715,752,701101.9TAUBERT JENNIFER LOfficer
Grant2025-08-2911,5211,332,634115.7FORMINARD ELIZABETHGeneral Counsel
Sell2025-08-22125,82422,548,655179.2DUATO JOAQUIN BOIXChief Executive Officer
Grant2025-08-22125,82412,817,691101.9DUATO JOAQUIN BOIXChief Executive Officer
Sell2025-08-1516,8202,975,571176.9WOLK JOSEPH JChief Financial Officer
Grant2025-08-1516,8201,713,453101.9WOLK JOSEPH JChief Financial Officer
Sell2025-07-1719,1373,129,830163.5REED JOHN COfficer
Grant2025-03-18130,85200.0DUATO JOAQUIN BOIXChief Executive Officer
Sell2025-02-256,9991,160,994165.9DECKER ROBERT JOfficer
Grant2025-02-256,999712,988101.9DECKER ROBERT JOfficer
Sell2025-02-1840362,928156.1SCHMID TIMOTHYOfficer

Congressional trading

$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$8001
$405012025-11$40501
$240022025-10$24002
$160012025-09$8001
$160012025-08$24002
$565022025-07$65001
$1295042025-06$16001
$160012025-05$64503
$400032025-04$32002
$2155022025-03$81002
DatePoliticianPartyChamberAmount ($)
Buy2025-12-09Lloyd DoggettDHouse$1,001 - $15,000
Sell2025-11-20Thomas H. Kean, Jr.RHouse$15,001 - $50,000
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Buy2025-11-07Ro KhannaDHouse$15,001 - $50,000
Buy2025-11-05Richard McCormickRHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Ro KhannaDHouse$1,001 - $15,000
Buy2025-10-30Ro KhannaDHouse$1,001 - $15,000
Sell2025-10-10Jared MoskowitzDHouse$1,001 - $15,000
Sell2025-10-10Jared MoskowitzDHouse$1,001 - $15,000
Buy2025-09-29Ro KhannaDHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000
Sell2025-08-19Kelly Louise MorrisonDHouse$1,001 - $15,000
Sell2025-08-14Julie JohnsonDHouse$1,001 - $15,000
Buy2025-08-04Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-07-31Thomas H. Kean, Jr.RHouse$15,001 - $50,000
Buy2025-07-25Ro KhannaDHouse$15,001 - $50,000
Buy2025-07-25Ro KhannaDHouse$15,001 - $50,000
Sell2025-07-01Ro KhannaDHouse$1,001 - $15,000
Sell2025-07-01Ro KhannaDHouse$1,001 - $15,000
Sell2025-07-01Ro KhannaDHouse$1,001 - $15,000
Sell2025-06-24Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-06-24Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-06-23Ro KhannaDHouse$15,001 - $50,000
Sell2025-06-20Ro KhannaDHouse$1,001 - $15,000
Sell2025-06-20Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-06-16Scott FranklinRHouse$15,001 - $50,000
Sell2025-06-12Pete SessionsRHouse$15,001 - $50,000
Buy2025-06-10Lloyd DoggettDHouse$1,001 - $15,000
Buy2025-05-30Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000
Sell2025-05-28Ro KhannaDHouse$1,001 - $15,000
Sell2025-05-19Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-09Ro KhannaDHouse$1,001 - $15,000
Buy2025-05-05Marjorie Taylor GreeneRHouse$1,001 - $15,000
Sell2025-04-29Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-04-23Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Sell2025-04-09Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-08Rob BresnahanRHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-01Julie JohnsonDHouse$1,001 - $15,000
Buy2025-03-31Gilbert Ray Cisneros, Jr.DHouse$15,001 - $50,000
Sell2025-03-24George WhitesidesDHouse$100,001 - $250,000
Sell2025-03-19Sheri BiggsRHouse$15,001 - $50,000
Sell2025-03-07Josh GottheimerDHouse$1,001 - $15,000
Buy2025-03-05Jefferson ShreveRHouse$15,001 - $50,000
Buy2025-03-04Lloyd DoggettDHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000
Buy2025-02-24Jefferson ShreveRHouse$15,001 - $50,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact